IMBIO LUNG

PORTFOLIO

BREAKTHROUGHS BY PHYSICIANS FOR PHYSICIANS

Imbio works with the most trusted names in healthcare to bring breakthrough image analysis to daily clinical care. Imbio is building an industry-leading portfolio to enable personalized imaging and diagnosis for millions of patients with chronic lung conditions.


lung density

LUNG DENSITY ANALYSIS ™ - Functional LDA (PRM)

FDA and Health Canada cleared, CE Mark certified

COPD affects more than 60 million people and is the 4th leading cause of death worldwide.1 Functional LDA is based on the patented Parametric Response Mapping (PRM) technology from the University of Michigan and helps enable data-based decisions for drug therapy, clinical procedures and other personalized patient care for patients with COPD.

Functional LDA is the only fully-automated, regulatory cleared image analysis providing a complete mapping of normal lung, air-trapping and areas of persistent low density (< -950 HU, which may be indicative of emphysema2) in a combined image to help visualize the components of COPD. LDA’s quantitative report provides volume and density classifications by % of lung volume for each lung region. LEARN MORE >


ld inspiration

LUNG DENSITY ANALYSIS ™ - Inspiration Analysis and Patient LungMap™

FDA and Health Canada cleared, CE Mark certified

More than 9 million current and former smokers are eligible for Lung Cancer screening in the U.S. LDA Inspiration Analysis for Lung Screening and basic COPD assessment provides rapid, automated quantification of areas < -950 HU (which may be indicative of emphysema2) based on a standard inspiratory chest CT. Inspiration Analysis includes Imbio Noise Reduction Technology (NRT) to aid quantification and visualization of low dose scans, and also includes Imbio’s Patient LungMap™ report to aid smoking cessation counseling. LEARN MORE >


lta

LUNG TEXTURE ANALYSIS ™ (CALIPER)

CE Mark certified, Investigational Use only in the U.S.

High resolution CT (HRCT) is a vital diagnostic tool for fibrotic conditions.3 Lung Texture Analysis ™ is based on the highly regarded CALIPER technology pioneered at the Mayo Clinic. LTA applies advanced computer vision to transform a standard chest CT into a detailed map and quantification of the lung textures that are key to identifying ILD’s and other fibrotic conditions (normal, ground glass, reticular, honeycomb and hyperlucent). Published studies have shown CALIPER to produce classification results comparable to expert radiologic judgment4 and quantification with significant correlations to survival and lung function.5,6 LEARN MORE >



airway analysis

AIRWAY ANALYSIS *

Airway remodeling is a key characteristic in multiple lung diseases. However, accurate, repeatable airway measurement is largely unattainable using manual-tracing techniques.7 Utilizing technology developed at the University of Heidelberg, Airway Analysis provides fully automated measurement of the airways by generation including lumen and total airway diameters, wall thickness and wall %, and additional statistics.



canary

CANARY (Computer-Aided Nodule Assessment and Risk Yield) *

Adenocarcinoma is the most common type of lung cancer and can vary in invasiveness. CANARY is a breakthrough noninvasive imaging technique from the Mayo Clinic designed to risk stratify adenocarcinomas. Initial studies have shown promising sensitivity and specificity to detect aggressive lesions8 and the ability classify nodules into distinct groups corresponding to good, intermediate, and poor postoperative disease free survival (DFS).9



rvlv

RV/LV Analysis *

Studies have shown an increased RV/LV diameter ratio to be a predictor of short-term mortality and adverse clinical events in patients with acute pulmonary embolism.10 RV/LV Analysis automatically segments each ventricle and analyzes the entire volume to determine maximum diameter measurements and calculate the RV/LV ratio. This avoids the variability inherent in visual assessment based on manual selection of an appropriate image slice and manual measurement.



* Airway Analysis, CANARY and RV/LV Analysis are currently available for research or investigational use only in all regions.


References
1. World Health Organization. Accessed online Feb 1, 2017. http://www.who.int/respiratory/copd/en/
2. ZA Azziz et al. HRCT diagnosis of diffuse parenchymal lung disease: interobserver variation. Thorax. 2004; 54: 506-511
3. Wang et al. Optimal threshold in CT quantification of emphysema. Eur Radiol. 2013 Apr;23(4):975-84
4. V Zavaletta, BJ Bartholmai, R Robb. High Resolution Multi-Detector CT Aided Tissue Analysis and Quantification of Lung Fibrosis. Acad Radiol. 2007 July ; 14(7): 772–787.
5. Maldonado, Moua, et al. Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J 2014; 43: 204–21
6. Raghunath, Moua, et al. Correlation of Quantitative Lung Tissue Characterization as Assessed by CALIPER With Pulmonary Function and 6-Minute Walk Test. Chest. 2011;140(4_MeetingAbstracts):1040A
7. Weinheimer, T Achenbach, et al. About Objective 3-D Analysis of Airway Geometry in Computerized Tomography. IEEE Trans Med Imaging. 2008 Jan;27(1):64-74
8. F Maldonado, JM. Boland, et al. Noninvasive Characterization of the Histopathologic Features of Pulmonary Nodules of the Lung Adenocarcinoma Spectrum using Computer-Aided Nodule Assessment and Risk Yield (CANARY)—A Pilot Study. J Thorac Oncol. 2013;8: 452-460.
9. S Raghunath, F Maldonado et al. Noninvasive Risk Stratification of Lung Adenocarcinoma using Quantitative Computed Tomography. J Thorac Oncol. 2014;9: 1698–1703.
10. T. Henzler, S. Roeger, et al. Pulmonary embolism: CT signs and cardiac biomarkers for predicting right ventricular dysfunction. European Respiratory Journal. 2012 39: 919-926.